Daniel F Sahm

Summary

Affiliation: Eurofins Medinet
Country: USA

Publications

  1. doi request reprint Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective
    Daniel F Sahm
    Eurofins Medinet Inc, Herndon, VA 20171, USA
    Postgrad Med 120:16-24. 2008
  2. pmc Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1790-7. 2003
  3. pmc Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States
    Deborah C Draghi
    Eurofins Medinet, Inc, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 52:2383-8. 2008
  4. ncbi request reprint Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000
    Ian A Critchley
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 20:100-7. 2002
  5. ncbi request reprint Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005)
    Daniel F Sahm
    Eurofins Medinet Anti infective Services, Inc, Herndon, VA 20171 4603, USA
    Otolaryngol Head Neck Surg 136:385-9. 2007
  6. ncbi request reprint Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy
    Mark E Jones
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA
    Int J Antimicrob Agents 23:240-6. 2004
  7. pmc In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy
    Richard P Wenzel
    Virginia Commonwealth University, Richmond Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:3089-98. 2003
  8. pmc Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002
    Robert K Flamm
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 48:2431-6. 2004
  9. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Int J Antimicrob Agents 20:76-85. 2002
  10. ncbi request reprint Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies
    James A Karlowsky
    Focus Bio Inova, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 40:S89-98. 2005

Collaborators

Detail Information

Publications74

  1. doi request reprint Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective
    Daniel F Sahm
    Eurofins Medinet Inc, Herndon, VA 20171, USA
    Postgrad Med 120:16-24. 2008
    ..There has been no change in the levofloxacin MIC(90) values for S pneumoniae and only rarely have resistant isolates of H influenzae and M catarrhalis been identified worldwide...
  2. pmc Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1790-7. 2003
    ..pneumoniae were susceptible to levofloxacin. If fluoroquinolones become a treatment option for pediatric patients, careful monitoring of fluoroquinolone susceptibilities will be increasingly important in future surveillance studies...
  3. pmc Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States
    Deborah C Draghi
    Eurofins Medinet, Inc, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 52:2383-8. 2008
    ..aureus strains (MICs, 0.5 microg/ml to 1.0 microg/ml and 1.0 microg/ml to 4.0 microg/ml, respectively). These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms...
  4. ncbi request reprint Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000
    Ian A Critchley
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 20:100-7. 2002
    ..Future studies to characterise resistant isolates by other molecular methods may ensure that the appropriate counter-measures can be taken to control the spread of resistant isolates...
  5. ncbi request reprint Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005)
    Daniel F Sahm
    Eurofins Medinet Anti infective Services, Inc, Herndon, VA 20171 4603, USA
    Otolaryngol Head Neck Surg 136:385-9. 2007
    ..To test the susceptibility of Streptococcus pneumoniae sinus isolates collected across the United States against commonly used antimicrobial agents...
  6. ncbi request reprint Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy
    Mark E Jones
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA
    Int J Antimicrob Agents 23:240-6. 2004
    ....
  7. pmc In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy
    Richard P Wenzel
    Virginia Commonwealth University, Richmond Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:3089-98. 2003
    ..The present study demonstrated that established parenteral expanded-spectrum cephalosporin antimicrobial agents retain significant in vitro activity against many clinically important gram-negative pathogens...
  8. pmc Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002
    Robert K Flamm
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 48:2431-6. 2004
    ..Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%)...
  9. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Int J Antimicrob Agents 20:76-85. 2002
    ..However, a significant regional variation in S. pneumoniae susceptibilities was observed, as was a decrease in beta-lactamase rates among H. influenzae from the 1999-2000 to 2000-2001 respiratory seasons...
  10. ncbi request reprint Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies
    James A Karlowsky
    Focus Bio Inova, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 40:S89-98. 2005
    ..Ongoing surveillance of P. aeruginosa is essential...
  11. ncbi request reprint Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:183-7. 2003
    ..4% of ciprofloxacin-resistant isolates (683 of 6560) were resistant to nitrofurantoin. An association between resistance to fluoroquinolones and nitrofurantoin in E. coli has not been previously reported and warrants further study...
  12. doi request reprint Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005
    Daniel F Sahm
    Eurofins Medinet Inc, Herndon, VA 20171 4603, USA
    Postgrad Med 120:8-15. 2008
    ....
  13. doi request reprint Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005
    Clyde Thornsberry
    Eurofins Medinet, Inc, Herndon, VA 20171, USA
    Postgrad Med 120:32-8. 2008
    ..Careful monitoring of multidrug resistance patterns will help guide appropriate therapeutic selection and may provide early detection of changes in resistance to more potent agents...
  14. doi request reprint Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions
    Daniel F Sahm
    Eurofins Medinet, Inc, Herndon, VA 20171 4603, USA
    Postgrad Med 120:53-9. 2008
    ..Institutions attempting to understand and control E coli resistance to fluoroquinolones should carefully examine the patient population and prevalence of resistance to other agents...
  15. ncbi request reprint Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002)
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:963-70. 2003
    ..53), and azithromycin (R2=0.41). Patient age, specimen source, and penicillin resistance were factors associated with antimicrobial resistance, particularly for nonfluoroquinolone antimicrobial agents...
  16. pmc Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001
    Ian A Critchley
    Focus Technologies, Inc, Herndon, Virginia, USA
    Antimicrob Agents Chemother 47:1689-93. 2003
    ..This study may serve as a baseline to monitor future changes in the susceptibility of gram-positive species to daptomycin following its introduction into clinical use...
  17. pmc Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    J Clin Microbiol 41:3339-43. 2003
    ..1% of the results for E. aerogenes isolates and 6.0% of the results for E. cloacae isolates tested with the Vitek system...
  18. pmc In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest
    Chris M Pillar
    Eurofins Medinet, Inc, Herndon, VA 20171, USA
    J Clin Microbiol 46:2862-7. 2008
    ..1, and 34% of the isolates, respectively. Further analysis regarding the suitability of the tigecycline Etest for testing S. marcescens, Acinetobacter spp., and S. pneumoniae is warranted...
  19. pmc Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1681-8. 2003
    ..aeruginosa and A. baumannii were constant or decreased only marginally (</=3%) from 1998 to 2001. Greater decreases in susceptibility rates were, however, observed for fluoroquinolones and ceftazidime among P. aeruginosa isolates...
  20. pmc Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:3155-60. 2003
    ..Whether such isolates have increased in prevalence over time remains unknown...
  21. pmc Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1672-80. 2003
    ..Ongoing surveillance of Enterobacteriaceae will be particularly important to monitor changes in fluoroquinolone susceptibility, as well as changes in the prevalence of isolates resistant to multiple classes of antimicrobial agents...
  22. doi request reprint In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin
    Chris M Pillar
    Eurofins Medinet, Inc, Anti Infective Services, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    J Antimicrob Chemother 61:595-602. 2008
    ....
  23. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999
    Ian A Critchley
    Focus Technologies, Inc formerly MRL, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Diagn Microbiol Infect Dis 42:129-35. 2002
    ..Given the higher rates of macrolide resistance reported in other countries and the seriousness of invasive infections, continued antimicrobial surveillance of S. pyogenes in the United States would be prudent...
  24. pmc In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV
    Mark E Jones
    Focus Technologies, Hilversum, The Netherlands Focus Technologies, Herndon, Virginia, USA
    Antimicrob Agents Chemother 46:1651-7. 2002
    ..aureus or S. pneumoniae was detected for the two NFQs. On the basis of their in vitro activities, these NFQ agents show potential for the treatment of infections caused by isolates resistant to currently available fluoroquinolones...
  25. pmc In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States
    Chris M Pillar
    Eurofins Medinet, Inc, Anti Infectives Services, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA
    Antimicrob Agents Chemother 52:4388-99. 2008
    ..Doripenem was the most active carbapenem tested against P. aeruginosa regardless of beta-lactam resistance...
  26. ncbi request reprint Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs
    Chris M Pillar
    Eurofins Medinet Anti infective Services, Herndon, VA 20171 4603, USA
    Diagn Microbiol Infect Dis 60:221-4. 2008
    ..MRSA rates were 55.7% among inpatients (53.9% MDR) and 48.7% among outpatients (30.7% MDR), with MDR rates increasing with age. These findings could impact the guidelines for the management and treatment of staphylococcal infections...
  27. pmc Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 46:2540-5. 2002
    ..8 to 17.0%) from 1995 to 2001 but demonstrated considerable regional and institutional variation in 2001. Therapies other than SXT may need to be considered in some locations...
  28. ncbi request reprint In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli
    Ian A Critchley
    Focus Technologies, Herndon, VA 20171, USA
    Chemotherapy 49:44-8. 2003
    ..Combination antimicrobial therapy is often necessary to eradicate infections caused by gram-negative bacteria...
  29. ncbi request reprint Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, Virginia 20171, USA
    Diagn Microbiol Infect Dis 42:53-8. 2002
    ..5 and 1 microg/mL inhibited 93.1 and 100% of M. catarrhalis isolates, respectively. We conclude that cefditoren is highly active in vitro against beta-lactamase-positive H. influenzae and M. catarrhalis...
  30. ncbi request reprint In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren
    James A Karlowsky
    Focus Technologies, Inc formerly MRL, 13665 Dulles Technology Drive, Herndon, Virginia 20171, USA
    Diagn Microbiol Infect Dis 42:59-64. 2002
    ..The potent in vitro activity of cefditoren against a recent US collection of pneumococci as demonstrated in this study supports its continued development for oral empiric therapy in outpatients with respiratory tract infections...
  31. pmc In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations
    Daniel F Sahm
    Focus Technologies, Inc, Herndon, Virginia 20171, USA
    J Clin Microbiol 40:669-74. 2002
    ..3% were resistant. Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints for nonmeningeal isolates of S. pneumoniae decreased the number of isolates interpreted as intermediate by 10% and as resistant by 3 to 4%...
  32. ncbi request reprint Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 19:21-31. 2002
    ..TRUST centralized in vitro and electronic (TSN) surveillance methods provided an effective strategy for monitoring trends in resistance...
  33. ncbi request reprint Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001
    Ian A Critchley
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    J Antimicrob Chemother 51:639-49. 2003
    ..The results of this study provide a benchmark of the activity of daptomycin against contemporary European isolates and will serve as a baseline to monitor future changes in the susceptibility of these organisms to daptomycin...
  34. pmc In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program
    Deborah C Draghi
    Focus Bio Inova, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 49:5024-32. 2005
    ..Nonetheless, careful and ongoing monitoring of the in vitro effectiveness of linezolid will be needed so that any changes to the current status may be detected as soon as possible...
  35. ncbi request reprint Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting
    Deborah C Draghi
    Focus Bio Inova, Inc, Herndon, VA 20171 4603, USA
    Diagn Microbiol Infect Dis 55:129-33. 2006
    ..The extensive similarities in resistance profiles between inpatient and outpatient MRSA have important implications for establishing outpatient management and treatment guidelines for staphylococcal infections...
  36. pmc Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 46:1989-92. 2002
    ..Future studies will determine how linezolid clinical use in Canada affects its in vitro activity...
  37. doi request reprint In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative
    Deborah C Draghi
    Eurofins Medinet, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA
    J Antimicrob Chemother 62:116-21. 2008
    ..The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel...
  38. pmc Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002)
    Mark E Jones
    Focus Technologies, Herndon, Virginia 20171, USA
    Ann Clin Microbiol Antimicrob 3:14. 2004
    ..Globally ICUs are encountering emergence and spread of antibiotic-resistant pathogens and for some pathogens there are few therapeutic options available...
  39. doi request reprint Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance
    Deborah C Draghi
    Eurofins Medinet, Inc, Herndon, VA 20171, USA
    Chemotherapy 54:91-100. 2008
    ..Given the dynamics of resistance development, careful monitoring of tigecycline activity against these organisms should remain a significant aspect of ongoing surveillance...
  40. ncbi request reprint The application of information technology to regional, national, and global surveillance of antimicrobial resistance
    Daniel F Sahm
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA
    Curr Pharm Des 9:969-74. 2003
    ..By virtue of information technology, large volumes of data can readily be managed and stored to allow timely and thorough analysis on institutional, regional, national, and global levels...
  41. pmc Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Ian A Critchley
    Focus Technologies, Inc formerly MRL, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 46:550-5. 2002
    ..influenzae strains, respectively; and 0.12 and 0.5 microg/ml for beta-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections...
  42. pmc Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003
    Ronald N Master
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Ann Clin Microbiol Antimicrob 3:1. 2004
    ..Previously, a single set of interpretative breakpoints was used for both meningeal and nonmeningeal isolates...
  43. pmc Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Ann Clin Microbiol Antimicrob 3:7. 2004
    ..Bloodstream infections are associated with significant patient morbidity and mortality. Antimicrobial susceptibility patterns should guide the choice of empiric antimicrobial regimens for patients with bacteremia...
  44. pmc Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002
    Mark E Jones
    Focus Technologies, Herndon, Virginia 20171, USA
    Ann Clin Microbiol Antimicrob 3:3. 2004
    ..The widespread emergence of resistance among bacterial species is a cause for concern. Current antibacterial susceptibility data among central nervous system (CNS) pathogens is important to define current prevalence of resistance...
  45. ncbi request reprint Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting?
    James A Karlowsky
    Focus Technologies, 13665 Dulles Technology Drive, Herndon, VA 20171 4603, USA
    Curr Opin Pharmacol 2:487-92. 2002
    ....
  46. pmc Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States
    David Styers
    Focus Bio Inova, Inc, Herndon, VA 20171, USA
    Ann Clin Microbiol Antimicrob 5:2. 2006
    ..aureus underscores the need for up-to-date and extensive insights regarding antimicrobial susceptibility trends. One approach to meet this need is analysis of clinical laboratory-based surveillance data...
  47. doi request reprint Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study
    Glenn S Tillotson
    Replidyne Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    J Antimicrob Chemother 62:109-15. 2008
    ....
  48. doi request reprint Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates
    Penny A Asbell
    Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Am J Ophthalmol 145:951-958. 2008
    ....
  49. pmc Relationship between antibiotic resistance in Streptococcus pneumoniae and that in Haemophilus influenzae: evidence for common selective pressure
    Mark E Jones
    Antimicrob Agents Chemother 46:3106-7. 2002
  50. doi request reprint Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005
    Penny A Asbell
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Cataract Refract Surg 34:814-8. 2008
    ..To report the nationwide prevalence of methicillin resistance in serious ocular infections involving Staphylococcus aureus and profile in vitro antimicrobial susceptibility of S aureus from ocular isolates over time...
  51. doi request reprint Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
    Francis F Arhin
    Targanta Therapeutics Inc, Saint Laurent, Quebec, Canada
    Diagn Microbiol Infect Dis 62:92-5. 2008
    ....
  52. pmc Longitudinal assessment of antipneumococcal susceptibility in the United States
    Mark E Jones
    Focus Technologies, Inc, Koniginneweg 11, 1217 KP Hilversum, The Netherlands
    Antimicrob Agents Chemother 46:2651-5. 2002
    ..4%; P < 0.001), and levofloxacin (0.3%; P = 0.017). Resistance to ceftriaxone (0.1%; P = 0.809) and moxifloxacin (0.03%; P = 0.570) decreased. Concurrently, multidrug resistance increased (P < 0.001) from 6.3% to 11.3%...
  53. ncbi request reprint Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative
    Mark E Jones
    Focus Technologies, Koninginneweg 11, 1217 KP, Hilversum, The Netherlands
    Int J Antimicrob Agents 19:119-23. 2002
    ..In summary, antimicrobial susceptibilities and the prevalence of beta-lactamase production in H. influenzae and M. catarrhalis in the United States has remained essentially unchanged from 1997-1998 to 1999...
  54. ncbi request reprint Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000
    Clyde Thornsberry
    Focus Technologies Inc, Nashville, TN, USA answers com
    Clin Infect Dis 34:S4-S16. 2002
    ..6%) and M. catarrhalis (86.2%-96.8%) also varied by region. Notable variation in regional antimicrobial resistance rates (S. pneumoniae) and beta-lactamase production (H. influenzae, M. catarrhalis) exists throughout the United States...
  55. doi request reprint Sporadic occurrences of fluoroquinolone-resistant Streptococcus pneumoniae in the United States: longitudinal analysis of institutions from the New England and West South Central regions during the TRUST 4-9 (2000-2005) Surveillance Studies
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, NJ 08869, USA
    Postgrad Med 120:25-31. 2008
    ..Based on data from the same institutions over 6 years, levofloxacin resistance among US pneumococci has been sporadic, nonclonal, and rare...
  56. doi request reprint Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, NJ 08869, USA
    Postgrad Med 120:39-45. 2008
    ..Considerable QRDR variability among these strains appears to be the result of sporadic independent mutational events as opposed to clonal expansion...
  57. ncbi request reprint Resistance issues and community-acquired respiratory infections
    Daniel F Sahm
    Focus Technologies, Inc Herndon, Virginia, USA
    Clin Cornerstone . 2003
    ..This article discusses some of the findings of the TRUST Program, particularly trends in Streptococcus pneumoniae resistance...
  58. ncbi request reprint Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy
    Mark E Jones
    Focus Technologies, Dwarsdijk 30, 3612AP Tienhoven, Netherlands
    Int J Antimicrob Agents 22:406-19. 2003
    ..For P. aeruginosa piperacillin-tazobactam, amikacin, imipenem and ceftazidime were the most active compounds tested irrespective of region. Surveillance data should be considered when selecting empirical therapy for treating SSTI...
  59. pmc Factors influencing fluoroquinolone resistance
    Daniel F Sahm
    Emerg Infect Dis 9:1651-4. 2003
  60. ncbi request reprint The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002
    Mark E Jones
    Focus Technologies Inc, Dwarsdijk 30, 3612AP Tienhoven, The Netherlands
    Diagn Microbiol Infect Dis 47:579-86. 2003
    ..3%-0.7%) and in Asia (3.0-3.2%), but little or no change was seen in Mexico (3.8%-0%) or Brazil or South Africa, where no levofloxacin resistant isolates were detected in either study period...
  61. pmc Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr
    Minggui Wang
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Antimicrob Agents Chemother 48:1400-1. 2004
    ..Sitafloxacin, BAYy3118, and premafloxacin had higher activity in vitro than ciprofloxacin against transconjugants and donors containing qnr. The donors had higher quinolone MICs than the transconjugants...
  62. ncbi request reprint Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003)
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development L L C, 1000 Route 202, Raritan, NJ, USA
    J Antimicrob Chemother 57:437-42. 2006
    ..Prevalence of single quinolone-resistance determining region (QRDR) mutations in Streptococcus pneumoniae was studied from nine institutions over 5 years to track the incidence of single QRDR mutations...
  63. pmc Reinterpretation of susceptibility data using current NCCLS breakpoint criteria
    Mark E Jones
    Antimicrob Agents Chemother 47:830. 2003
  64. ncbi request reprint Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents
    Mark E Jones
    J Antimicrob Chemother 51:196-9. 2003
  65. ncbi request reprint The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000
    Mark E Jones
    Focus Technologies Inc, Hilversum, The Netherlands
    Chemotherapy 48:232-7. 2002
    ..Increases in penicillin-resistant Streptococcus pneumoniae have been documented worldwide...
  66. ncbi request reprint Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001
    James R Johnson
    Mucosal and Vaccine Research Center, Veterans Affairs Medical Center, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55417, USA
    J Infect Dis 190:1739-44. 2004
    ..Increases in antimicrobial resistance in Escherichia coli have been paralleled by an increasing incidence of E. coli sepsis, suggesting a possible link between resistance and virulence...
  67. pmc Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States
    Minggui Wang
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Antimicrob Agents Chemother 48:1295-9. 2004
    ..Plasmid-determined quinolone resistance contributes to the increasing quinolone resistance of K. pneumoniae isolates and to the linkage previously observed between resistance to quinolones and the latest beta-lactam antibiotics...
  68. pmc In vitro antimicrobial activity of doripenem, a new carbapenem
    Yigong Ge
    Peninsula Pharmaceuticals, Alameda, California 94502, USA
    Antimicrob Agents Chemother 48:1384-96. 2004
    ..Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens...
  69. pmc In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States
    Yigong Ge
    Cerexa, Inc, Alameda, California, USA
    Antimicrob Agents Chemother 52:3398-407. 2008
    ..Ceftaroline was very potent against bacteria found in community- and hospital-acquired infections, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and common Enterobacteriaceae spp...
  70. pmc Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing
    Francis F Arhin
    Targanta Therapeutics, Saint Laurent, Quebec, Canada H4S 2A1
    Antimicrob Agents Chemother 52:1597-603. 2008
    ..Moreover, the combination of data from MIC and [(14)C]oritavancin recovery studies supports the revision of the oritavancin broth microdilution method to include polysorbate 80 throughout the assay...
  71. pmc Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 1217 KP Hilversum, The Netherlands
    J Clin Microbiol 40:1063-6. 2002
    ..Pulsed-field gel electrophoresis of genomic DNA following SmaI digestion demonstrated identical patterns for each of the nine isolates, suggesting intra- and interhospital dissemination of a BLNAR clone...
  72. ncbi request reprint Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000)
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 1000 Route 202, Raritan, NJ 08869, USA
    J Antimicrob Chemother 52:168-75. 2003
    ..To detect relatedness among 68 (0.5%) of 13 795 US clinical isolates of Streptococcus pneumoniae from the TRUST 3 (1998-1999) and TRUST 4 (1999-2000) surveillance studies that were resistant to levofloxacin (MIC > or = 8 mg/l)...
  73. pmc Bactericidal activity and resistance development profiling of dalbavancin
    Beth P Goldstein
    Pfizer Inc, Pfizer Global Pharmaceuticals, King of Prussia, PA, USA
    Antimicrob Agents Chemother 51:1150-4. 2007
    ..These observations suggest that dalbavancin will be an effective choice for the management of patients with SSSIs...
  74. pmc Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000
    Todd A Davies
    Ortho McNeil Pharmaceutical, Raritan, New Jersey 08869, USA
    Antimicrob Agents Chemother 46:119-24. 2002
    ..Although there has been an increase in the prevalence of single-step mutants, the increase may have been overestimated due in part to differences in geographical distribution for the two sets of isolates...